• Insider Monkey

    ChatGPT Stock Portfolio: Top 10 Picks

    In this article, we will take a look at ChatGPT stock portfolio. To see more such companies, go directly to ChatGPT Stock Portfolio: Top 5 Picks. If there’s one thing that can be learned from literally hundreds of ChatGPT-related posts out there claiming that the AI chatbot has successfully beaten the market, it’s that ChatGPT’s […]

  • TheStreet.com

    Bearish Bets: 3 Stocks You Should Really Consider Shorting This Week

    Using technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet's Quant Ratings, we zero in on three names. While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. Johnson & Johnson recently was downgraded to Hold with a C+ rating by TheStreet's Quant Ratings.

  • Motley Fool

    Buy the Dip On These Warren Buffett Stocks

    If you're like Warren Buffett, you favor solid companies that perform over the long term -- and, at the same time, reward investors with passive income. Buffett has made his fortune -- and the fortune of others as Berkshire Hathaway chairman -- by sticking to that idea. Well, an opportunity is here for two Buffett favorites.

  • Motley Fool

    Investing $43 in This Stock per Week for 5 Years Could Give You $500 in Annual Dividend Income

    If you're thinking of investing in Pfizer (NYSE: PFE) to generate some passive income from your portfolio, you won't need to spend very much to do so, provided that you're willing to play the long game. Building up a passive income stream is often a lot more manageable when you can do it piece by piece rather than paying out a large lump sum. Dollar-cost averaging (DCA) refers to buying a few shares of a stock here and there over a period of time so that you don't need a lump sum to reach your target position size.

  • Motley Fool

    3 No-Brainer Stocks to Buy for Under $100 Right Now

    Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Novocure (NASDAQ: NVCR), and Pfizer (NYSE: PFE). David Jagielski (CRISPR Therapeutics):  Shares of CRISPR Therapeutics are trading below $70, but it may not be long before they take off. The company has a promising gene-editing therapy in exa-cel for rare blood disorders beta-thalassemia and sickle cell disease that it has been working on with Vertex Pharmaceuticals.

  • Bloomberg

    Tylenol-Maker Kenvue Poised to Get Wall Street Ratings After IPO

    (Bloomberg) -- Kenvue Inc., the consumer health business that Johnson & Johnson spun off this month, will be eligible for ratings from a slew of major Wall Street banks next week, offering a chance to see how analysts are assessing initial public offerings amid the latest equities volatility and recession worries. Most Read from BloombergBiden, McCarthy Forge Debt Deal in Bid to Avert US DefaultWorld’s Richest Man Throws In Towel on Beverly Hills HotelKey Takeaways From Deal Biden, GOP Sealed to

  • Investor's Business Daily

    Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

    An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

  • Insider Monkey

    Louis Navellier’s 2023 Portfolio: 15 Growth Stocks to Watch

    In this article, we discuss 15 growth stocks to watch in Louis Navellier’s 2023 portfolio. If you want to see more stocks in this selection, check out Louis Navellier’s 2023 Portfolio: 5 Growth Stocks to Watch. According to a report featured on Markets Insider in October 2022, Louis Navellier of Navellier & Associates said that the […]

  • The Wall Street Journal

    Next Covid Boosters to Target New Strain

    Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S.

  • Zacks

    Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation

    Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.

  • Barrons.com

    Drugmakers Released a Ton of New Cancer Treatment Data. The Biggest Developments.

    Ahead of the American Society of Clinical Oncology meeting, Pfizer, Merck, and other companies released scientific abstracts of papers that they'll present at the annual meeting.

  • Zacks

    Pfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults

    Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.

  • Zacks

    Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study

    A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.

  • Investor's Business Daily

    Is Novavax Stock A Buy Or A Sell As Shares Stage A Comeback On A Cost-Cutting Plan?

    Novavax stock is on the rise after announcing a cost-cutting plan and bullish sales guidance. Is NVAX stock a buy or a sell today?

  • Zacks

    Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use

    Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.

  • Yahoo Finance Video

    Pfizer weight loss drug may be as effective as competitors: Study

    Yahoo Finance Live health care reporter Anjalee Khemlani details the clinical trial results of Pfizer's weight loss drug Danuglipron, how it compares to Novo Nordisk's Ozempic, and examines the adoption of weight loss drugs in the health and wellness space.

  • Benzinga

    Amended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced Purchases

    The European Commission (EC) had agreed with BioNTech SE (NASDAQ: BNTX) and Pfizer Inc (NYSE: PFE) on adapting the existing contract on vaccines against Covid-19, including a reduction in the quantity of doses purchased by EU countries under the contract and pushing the delivery deadline to 2026. "The amendment to the existing vaccines supply contract takes into account the improved epidemiological situation while continuing to ensure access to the latest available version of the vaccine should

  • Motley Fool

    Want Passive Income Forever? Buy These 2 Magnificent Stocks Now

    Many investors actively seek dividend stocks, and who can blame them? Choosing the right dividend stocks is arguably the best way to avoid this risk: Not all dividend stocks are created equal. With that said, let's turn our attention to two companies that are practically passive income machines and will likely continue rewarding shareholders with payout increases for a long time: Johnson & Johnson (NYSE: JNJ) and Apple (NASDAQ: AAPL).

  • Zacks

    Solid Earnings Fuel Potential Bull Market in Medical Devices

    CNBC's Jim Cramer predicts a booming bull market for medical devices, with positive earnings reports across the space. INMD, JNJ, ISRG and GEHC can emerge as potential winners.

  • PR Newswire

    Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

    Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that Nuvaxovid™ (NVX-CoV2373) has been recommended for full Marketing Authorization (MA) for use as a primary series in individuals aged 12 and older and as a booster in individuals aged 18 and older for the prevention of COVID-19 in the European Union (EU) following a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the Europea

  • Simply Wall St.

    Is AbbVie Inc.'s (NYSE:ABBV) ROE Of 57% Impressive?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

  • Business Wire

    Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress

    CAMBRIDGE, Mass. & OSAKA, Japan, May 26, 2023--Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 2-6, 2023, in Chicago, Ill. and the 31st Congress of the European Hematology Association (EHA), June 8-11, 2023, in Frankfurt, Germany.

  • Financial Times

    Brussels and Pfizer agree deal to cut supply of Covid vaccines

    Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes

  • Reuters

    UPDATE 1-Moderna says looking for opportunities in China after registering legal entity

    U.S. vaccine maker Moderna said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy. The U.S. pharmaceutical and biotech firm registered a unit called Moderna (China) Biotech Limited in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha. "We are exploring opportunities to engage in the market and bring the power of Moderna’s mRNA platform to the people of China," a spokesperson said in response to a query from Reuters.

  • Reuters

    Moderna says looking for opportunities in China after registering legal entity

    BEIJING (Reuters) -Vaccine maker Moderna Inc said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy. The U.S. biotech firm registered a unit called Moderna (China) Biotech Ltd in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha. "We are exploring opportunities to engage in the market and bring the power of Moderna's mRNA platform to the people of China," a company spokesperson said in response to a query from Reuters.